# Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

> **NCT06239311** · PHASE3 · RECRUITING · sponsor: **medac GmbH** · enrollment: 277 (estimated)

## Conditions studied

- Moderate to Severe Atopic Dermatitis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06239311
- **Lead sponsor:** medac GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-27
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 277 (ESTIMATED)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239311, "Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06239311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*